Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Zosano Pharma Corp (ZSAN) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/19/2022 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
06/07/2022 4 Matthews Christine (CFO) has filed a Form 4 on Zosano Pharma Corp
Txns: Sold 82 shares @ $0.71, valued at $58.2
06/07/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/03/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/18/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
05/18/2022 8-K Quarterly results
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/13/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/29/2022 8-K Quarterly results
04/29/2022 10-K/A Annual Report for the period ended December 31, 2021 [amend]
04/11/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation of Zosano Pharma Corporation",
"Zosano Pharma Announces Reverse Stock Split Effective Today ZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022"
04/01/2022 4 Matthews Christine (CFO) has filed a Form 4 on Zosano Pharma Corp
Txns: Sold 8,116 shares @ $0.2101, valued at $1.7k
04/01/2022 4 KELLERMAN DONALD J (VP, Clinical Dev & Med Affairs) has filed a Form 4 on Zosano Pharma Corp
Txns: Sold 4,006 shares @ $0.2101, valued at $841.7
04/01/2022 4 Lo Steven (CEO) has filed a Form 4 on Zosano Pharma Corp
Txns: Sold 23,633 shares @ $0.2101, valued at $5k
04/01/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/17/2022 10-K Annual Report for the period ended December 31, 2021
03/17/2022 8-K Quarterly results
Docs: "Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results"
02/25/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/18/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/11/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/11/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/09/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, between Zosano Pharma Corporation and Maxim Group LLC",
"Form of Series F Warrant",
"Opinion of Latham & Watkins LLP",
"Form of Warrant Agency Agreement",
"Form of Voting Agreement"
02/09/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/08/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/31/2022 8-K Investor presentation
Docs: "DESIGNED TO ADDRESS UNMET NEEDS IN MIGRAINE 7"
01/24/2022 8-K Other Events  Interactive Data
01/05/2022 8-K Other Events  Interactive Data
12/13/2021 8-K Quarterly results
12/09/2021 4 Yang Elaine (Director) has filed a Form 4 on Zosano Pharma Corp
Txns: Granted 90,000 options to buy @ $0.558, valued at $50.2k
12/09/2021 3 Yang Elaine (Director) has filed a Form 3 on Zosano Pharma Corp
11/30/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/24/2021 4 GREATHOUSE KENNETH (Director) has filed a Form 4 on Zosano Pharma Corp
Txns: Sold 10,000 shares @ $0.6018, valued at $6k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy